治疗hypervolemic或euvolemic低钠血症与心力衰竭、肝硬化,或不适当的抗利尿激素综合征tolvaptan:临床评估。

文章的细节

引用

复制到剪贴板

Nemerovski C,哈钦森DJ

治疗hypervolemic或euvolemic低钠血症与心力衰竭、肝硬化,或不适当的抗利尿激素综合征tolvaptan:临床评估。

其他。2010年6月,32 (6):1015 - 32。doi: 10.1016 / j.clinthera.2010.06.015。

PubMed ID

20637957 (在PubMed

]

文摘

背景:Tolvaptan是口服nonpeptide选择性抗利尿激素V(2)受体拮抗剂显示治疗临床相关hypervolemic或euvolemic低钠血症与心力衰竭、肝硬化,或不适当的抗利尿激素综合症。目的:本文的目的是审查的药理学功效,和耐受性tolvaptan hypervolemic或euvolemic低钠血症的治疗,心脏衰竭,常染色体显性遗传性多囊肾病(ADPKD)。确定方法:文章利用MEDLINE(1966 - 2010年2月28日)和EMBASE(1947 - 2010年2月28日)。摘要和诉讼的年会(2007 - 2009),美国心脏协会,欧洲心脏病学会和美国肾脏病学会搜索,以找到更多的相关出版物。必威国际app必威国际app搜索进行了使用条款tolvaptan,加压素拮抗剂,心脏衰竭,多囊肾疾病、低钠血症、药物相互作用、药物动力学、药理学。综述了确定出版物的引用列表额外的引用。所有临床试验评估了使用tolvaptan hypervolemic / euvolemic低钠血症或心力衰竭的管理包括人类,无论研究设计。结果:共有9试验确定。治疗低钠血症,tolvaptan显著增加血清钠浓度与安慰剂比较治疗4天(3.62 [2.68]vs 0.25[2.08]更易与L,分别;30 (P < 0.001)和6.22(4.10)和1.66(3.59)更易/ L; P < 0.001). In the clinical trials in patients with heart failure, tolvaptan at doses of 30, 60, and 90 mg/d was associated with mean weight changes of -1.80, -2.10, and -2.05 kg, respectively, versus -0.60 kg with placebo (P = 0.002, P = 0.002, and P = 0.009). Trials of tolvaptan in humans with ADPKD are ongoing. Overall, mortality rates were not significantly altered with tolvaptan compared with placebo (25.9% vs 26.3%). The most commonly reported adverse events associated with tolvaptan in clinical trials were dry mouth (4.2%-23.0%), thirst (7.7%-40.3%), and polyuria (0.6%-31.7%), all consistent with the mechanism of action of the drug. CONCLUSION: Based on findings from clinical trials to date, tolvaptan is effective for the correction of hyponatremia but has not been associated with significant improvements in mortality in patients with heart failure compared with placebo, and its utility in the treatment of ADPKD in humans remains to be determined.

DrugBank数据引用了这篇文章

药物

Tolvaptan

药物靶点

药物	目标	类	生物	药理作用	行动
Tolvaptan	后叶加压素V1a受体	蛋白质	人类	没有	拮抗剂	细节